

Minutes

BRI Institutional Biosafety Committee Institutional Biosafety Committee 8/12/2025 1:00 pm Zoom

1 Statements of Confidentiality and Conflicts of Interest

Quorum and Meeting Access: The Chair called the meeting to order at 1:00 pm and noted that the meeting was open to the public. Quorum existed at the start of the meeting with 9 voting members present. A guorum was maintained for the entire meeting.

Confidentiality: The Chair reminded the committee that while the meeting is open to the public, the information discussed during the meeting should be treated as confidential.

Conflict of Interest: The Chair asked the committee if any members needed to declare a conflict of interest with respect to any matter on the agenda. The Chair notified committee members that if they had a conflict of interest, they must leave the room during the final discussion and voting on that IBC submission.

2 Attendees

Committee Members Present

Lewis Bowen III (Finance and Administration)

Kunal Gupta (Neurosurgery)
Anna Huppler (Pediatrics)

Eric Jensen (Research Office)

Tyce Kearl (Medicine)

Nikki Lytle (Surgery)

Angela Mathison (Surgery)

Qizhen Shi (Pediatrics)
Matthew Surdel (Medicine)

Committee Members Absent

Kenneth Allen (Research Office)

James Case (Non-MCW)

Lezi E (Cell Biology, Neurobiology and Anatomy)

Biological Safety Officer

R/SNA Technology Expert

R/SNA Technology Expert

Animal Containment Expert

R/SNA Technology Expert

UCT Export

HGT Expert

R/SNA Technology Expert

R/SNA Technology Expert

R/SNA Technology Expert

R/SNA Technology Expert

Alternate Animal Containment

Expert, Non-Voting

Non-Affiliated Member

R/SNA Technology Expert

Benjamin Gantner (Medicine) Laura Stephens (Non-MCW) Chair

Non-Affiliated Member

3 Meeting Minutes Reviewed at this Meeting

7/8/2025 (Zoom)

Motion: Minutes Approved

Yes Votes: 9
No Votes: 0
Abstained: 0
Recused: 0
Total Votes: 9

4 New Business

1. Administrative Report

The Chair asked the Committee Members to review the Administrative Report and then invited discussion. No concerns were raised.

2. Exempt Rodent Report

The Exempt Rodent Report was provided to the Committee members.

5 Application Reviews

IBC20250025 Blood Vessel and Stem Cell Regulators in Zebrafish

Principal Investigator: Wade Sugden

Motion: Decision Pending Changes

Yes Votes: 9
No Votes: 0
Abstained: 0
Recused: 0
Total Votes: 9

NIH Guidelines: Section III-D-4, Section III-E, Section III-F-1, Section III-F-2,

Section III-F-8 (C-I), Section III-F-8 (C-II)

Biosafety Level(s): BSL1, BSL2

Deliberations:

The Vice Chair introduced this new Institutional Biosafety Committee (IBC) application, allowing the Primary Reviewer to describe the study. The Principal Investigator (PI) proposes to study the developmental signals required for the endothelial-to-hematopoietic transition in the process of hematopoietic stem cell production. The lab uses a zebrafish model, including live-imaging and chemical/genetic screens. Clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 experiments are done with enzyme and guide RNA delivered as separate components with the guide RNA not targeting human genes. Additional work is done in human primary cells and cell lines. Work with human oncogenes and tumor suppressors occurs via lipofectamine transfection of human cells. The application uses microorganisms (Escherichia (E.) coli K12), recombinant DNA (rDNA) (including cloning vectors, expression vectors, guide RNA (gRNA), morpholinos, polymerase chain reaction (PCR) amplicons, and sense/antisense RNA), and human source materials (including hematopoietic cells, peripheral blood mononuclear cells (PBMCs), HEK293, induced pluripotent stem cells (iPSCs), and human umbilical vein endothelial cells (HUVEC)). The Committee confirmed that all personnel listed in the application completed safety training appropriate for work with the materials described. The Primary and Secondary Reviewers requested a few clarifications, including whether E. coli and several human cells lines are used in the study or only stored in the lab. The Animal Containment Expert (ACE) and the Biological Safety Officer (BSO) had no

5 Application Reviews

additional concerns. Upon a motion duly made by the Primary Reviewer and seconded, the Committee voted to approve this new application pending the requested changes.

6 Adjournment

There being no further business, the meeting was adjourned at 1:24 pm. The next regularly scheduled meeting will be held on Tuesday, September 9, 2025 at 1:00 pm in Zoom.